Clinical Study Report (Abbreviated) — GLPI103-101 (FIH / SAD)
📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. An abbreviated clinical study report for the first-in-human single-ascending-dose (SAD) study.
Why it exists. The first human study escalates single doses to establish initial safety, tolerability, and PK. Its abbreviated report documents the starting point of clinical development and the doses carried forward.
How it is produced here. This is an early-phase (first-in-human / Phase 2) report written as a short narrative. It is a portfolio stand-in, kept deliberately consistent with the rest of the program (the doses, the pharmacology, the safety story all line up).
Format & governing standard. ICH E3 (abbreviated report — early-phase)
Clinical Study Report (Abbreviated) — GLPI103-101 (FIH / SAD)
| Field | Value |
|---|---|
| Document ID | CSR-101 |
| Version | 2.0 |
| Study No. | GLPI103-101 |
| Compound | GLPI-103 (GLP-1/APJ dual agonist) |
| Standard | ICH E3 (abbreviated report — early-phase) |
| Confidentiality | Confidential — portfolio use |
[MOCK — deep-knowledge assumption]No FIH data are simulated; values are illustrative and consistent with the IB (IB-001) and REF-002.
Change History
| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0 | 2026-06-29 | Clinical | Initial abbreviated CSR |
| 2.0 | 2026-06-30 | Clinical | Expanded to fuller ICH E3 structure (ethics, design, disposition, PK/PD, safety) |
1. Synopsis
| Item | Description |
|---|---|
| Design | Phase 1, randomized, double-blind, placebo-controlled, Single Ascending Dose (SAD) |
| Population | Healthy adult volunteers |
| N | 40 (5 ascending-dose cohorts × 8; 6 active : 2 placebo) |
| Objectives | Safety, tolerability, PK; PD biomarker engagement (plasma apelin) |
| Doses | Sequential single doses with sentinel dosing and stopping rules |
| Primary outcome | Incidence/severity of TEAEs; PK parameters (Cmax, AUC, t½) |
2. Ethics and Study Administration
The study was conducted per the Declaration of Helsinki, ICH E6(R3) GCP, and applicable regulations, with IRB/IEC approval and written informed consent before any procedure. An independent DSMB reviewed cumulative safety before each escalation. Conducted at a single clinical pharmacology unit [MOCK].
3. Objectives
- Primary: characterize single-dose safety/tolerability and PK.
- Secondary/exploratory: PD biomarkers (plasma apelin, glucose/insulin responses); immunogenicity (anti-drug antibodies).
4. Investigational Plan
- Design: double-blind, placebo-controlled, sequential ascending single-dose cohorts. Within each cohort of 8, 6 received GLPI-103 and 2 placebo.
- Dose levels
[MOCK]: five ascending single doses spanning the projected therapeutic range, with the starting dose MABEL/NOAEL-justified (M2.4). - Sentinel dosing: the first 2 subjects per cohort (1 active : 1 placebo) were dosed and observed ≥24 h before the remainder.
- Escalation/stopping rules: escalation required DSMB review of safety; predefined stopping criteria (e.g., ≥2 subjects with the same severe related TEAE, any related SAE) governed the study.
- Eligibility: healthy adults 18–55 y, BMI 18–30 kg/m², no clinically significant disease; key exclusions: personal/family history of MTC or MEN 2, pancreatitis history.
- Assessments: intensive PK sampling over the dosing interval; continuous safety monitoring (AEs, vital signs, ECG, clinical labs).
5. Study Subjects and Disposition
40 subjects were randomized and dosed; all completed the in-unit period and the follow-up visit; no discontinuations [MOCK]. Demographics were typical of a healthy-volunteer population (predominantly younger adults, balanced sex).
6. Pharmacokinetic and Pharmacodynamic Results [MOCK]
| Parameter | Finding |
|---|---|
| Cmax / AUC | approximately dose-proportional across the tested range |
| t½ | long terminal half-life supporting once-weekly dosing |
| Accumulation | not applicable (single dose) |
| PD | dose-dependent plasma apelin engagement and a glucose-lowering signal |
| Immunogenicity | low-titre, non-neutralizing; no PK/PD impact |
7. Safety Results [MOCK]
- TEAEs: most frequent were mild, transient gastrointestinal symptoms (nausea); no dose-limiting toxicity.
- SAEs/deaths: none.
- Laboratory/ECG/vital signs: no clinically significant trends; no QT signal of concern (consistent with nonclinical hERG/telemetry).
8. Discussion and Conclusions
GLPI-103 single doses were well tolerated across the tested range, with a PK profile supporting once-weekly dosing and PD evidence of target engagement, justifying progression to multiple-dose evaluation (GLPI103-102). Findings inform the Reference Safety Information (IB-001 §7).
9. Limitations and Cross-References
As a single-dose FIH study in healthy volunteers, this report does not address efficacy, steady-state PK, or long-term safety. The single-dose PK is integrated into the population-PK model and clinical-pharmacology summary (CLINPHARM-002; M2.7.2); the cardiac-safety context (no QT/hERG liability) is detailed in CLINPHARM-003; immunogenicity is summarized in IMMUNO-001. All early-phase values are illustrative [MOCK].
Comments (0)
No comments yet. Be the first to say something!